Shih-Min A Huang
Overview
Explore the profile of Shih-Min A Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1882
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barberis C, Erdman P, Czekaj M, Fire L, Pribish J, Tserlin E, et al.
Bioorg Med Chem Lett
. 2020 Oct;
30(23):127625.
PMID: 33096160
N-substituted azaindoles were discovered as potent pan-PIM inhibitors. Lead optimization, guided by structure and focused on physico-chemical properties allowed us to solve inherent hERG and permeability liabilities, and provided compound...
2.
Wagle M, Castillo J, Srinivasan S, Holcomb T, Yuen K, Kadel E, et al.
Cancer Immunol Res
. 2020 Apr;
8(7):844-850.
PMID: 32321776
Prostate cancer is the second leading cause of cancer-related death in men. Despite having a relatively lower tumor mutational burden than most tumor types, multiple gene fusions such as have...
3.
Varga A, Soria J, Hollebecque A, LoRusso P, Bendell J, Huang S, et al.
Clin Cancer Res
. 2019 Dec;
26(6):1229-1236.
PMID: 31848189
Purpose: ERK1/2 signaling can be dysregulated in cancer. GDC-0994 is an oral inhibitor of ERK1/2. A first-in-human, phase I dose escalation study of GDC-0994 was conducted in patients with locally...
4.
Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, et al.
Clin Cancer Res
. 2019 Oct;
25(22):6709-6720.
PMID: 31573956
Purpose: The success of checkpoint blockade has led to a significant increase in the development of a broad range of immunomodulatory molecules for the treatment of cancer, including agonists against...
5.
Trabucco S, Gowen K, Maund S, Sanford E, Fabrizio D, Hall M, et al.
J Mol Diagn
. 2019 Aug;
21(6):1053-1066.
PMID: 31445211
Microsatellite instability (MSI) is an important biomarker for predicting response to immune checkpoint inhibitor therapy, as emphasized by the recent checkpoint inhibitor approval for MSI-high (MSI-H) solid tumors. Herein, we...
6.
Castillo J, Wu E, Lowe C, Srinivasan S, McCord R, Wagle M, et al.
Cancer Res
. 2019 Jun;
79(15):3916-3927.
PMID: 31182547
Regulatory T cells (Treg) are immunosuppressive and negatively impact response to cancer immunotherapies. CREB-binding protein (CBP) and p300 are closely related acetyltransferases and transcriptional coactivators. Here, we evaluate the mechanisms...
7.
Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors - Lead optimization - Part III
Barberis C, Pribish J, Tserlin E, Gross A, Czekaj M, Barrague M, et al.
Bioorg Med Chem Lett
. 2018 Dec;
29(3):491-495.
PMID: 30553737
N-substituted azaindoles were discovered as promising pan-PIM inhibitors. Lead optimization is described en route toward the identification of a clinical candidate. Modulation of physico-chemical properties allowed to solve inherent hERG...
8.
Wagle M, Kirouac D, Klijn C, Liu B, Mahajan S, Junttila M, et al.
NPJ Precis Oncol
. 2018 Jun;
2(1):7.
PMID: 29872725
- and -mutant tumors are often dependent on MAPK signaling for proliferation and survival and thus sensitive to MAPK pathway inhibitors. However, clinical studies have shown that MEK inhibitors are...
9.
Merchant M, Moffat J, Schaefer G, Chan J, Wang X, Orr C, et al.
PLoS One
. 2018 Jan;
13(1):e0192059.
PMID: 29370292
[This corrects the article DOI: 10.1371/journal.pone.0185862.].
10.
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Merchant M, Moffat J, Schaefer G, Chan J, Wang X, Orr C, et al.
PLoS One
. 2017 Oct;
12(10):e0185862.
PMID: 28982154
Mitogen-activated protein kinase (MAPK) pathway dysregulation is implicated in >30% of all cancers, rationalizing the development of RAF, MEK and ERK inhibitors. While BRAF and MEK inhibitors improve BRAF mutant...